Loading
A phase 2 trial of Aglatimagene besadenovec in prostate cancer, run by Candel Therapeutics, Inc., now recruiting.
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec is a phase 2 interventional study registered as NCT07332000 by Candel Therapeutics, Inc., with 45 participants planned, started 2025-10-30 and due to reach its primary completion in 2027-02. Interventions recorded: aglatimagene besadenovec + valacyclovir, External Beam Radiation Therapy (EBRT). Conditions listed: Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Aglatimagene besadenovec, Candel Therapeutics, Prostate cancer.
Shares Aglatimagene besadenovec, Candel Therapeutics, Prostate cancer.
Shares Localised prostate cancer, intermediate risk, Prostate cancer.
Shares Localised prostate cancer, intermediate risk, Prostate cancer.
Shares Localised prostate cancer, intermediate risk, Prostate cancer.
Shares Localised prostate cancer, intermediate risk, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/